Top

General Thoracic and Cardiovascular Surgery

Published in:

01-05-2013 | Current Topics Review Article

Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma

Authors: Yasushi Toh, Akinori Egashira, Manabu Yamamoto

Published in: General Thoracic and Cardiovascular Surgery | Issue 5/2013

Abstract

Alterations in the regulation of gene expression that do not involve a change in the DNA sequence have been increasingly recognized as an important key event of carcinogenesis, referred to as “epigenetic” changes. Major epigenetic mechanisms include the methylation of cytosines in DNA, changes of histone and chromatin structure by covalent posttranslational modifications of histone proteins and alterations in the expression of microRNAs. These epigenetic alterations have also been identified in esophageal squamous cell carcinoma (ESCC). In this brief review, we will discuss DNA hypermethylation of the tumor suppressor gene promoters, histone modifications including histone acetylation/deacetylation and histone methylation and microRNAs in ESCC. Clinical implications of these epigenetic alterations in ESCC will be also discussed.

Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993–2001. Jpn J Clin Oncol. 2008;38:464–8.PubMedCrossRef

Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.PubMedCrossRef

Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2–9.PubMedCrossRef

Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S, Egashira A, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15:135–44.PubMedCrossRef

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRef

You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22:9–20.PubMedCrossRef

Sawan C, Vaissiere T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res. 2008;642:1–13.PubMedCrossRef

Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069–78.PubMedCrossRef

Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet. 2007;16(Spec No 1):R28–49.PubMedCrossRef

10.

Zhao R, Casson AG. Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer. Curr Cancer Drug Targets. 2008;8:509–21.PubMedCrossRef

11.

Li JS, Ying JM, Wang XW, Wang ZH, Tao Q, Li LL. Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma. Chin J Cancer. 2013;3:3–11.CrossRef

12.

Zhang XM, Guo MZ. The value of epigenetic markers in esophageal cancer. Front Med China. 2010;4:378–84.PubMedCrossRef

13.

Baba Y, Watanabe M, Baba H. A review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today. 2013 (Epub ahead of print).

14.

Herceg Z, Ushijima T. Introduction: epigenetics and cancer. Adv Genet. 2010;70:1–23.PubMedCrossRef

15.

Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11:726–34.PubMedCrossRef

16.

Megee PC, Morgan BA, Smith MM. Histone H4 and the maintenance of genome integrity. Genes Dev. 1995;9:1716–27.PubMedCrossRef

17.

Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.PubMedCrossRef

18.

Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008;659:40–8.PubMedCrossRef

19.

Tzao C, Tung HJ, Jin JS, Sun GH, Hsu HS, Chen BH, et al. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol. 2009;22:252–60.PubMedCrossRef

20.

Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40:741–50.PubMedCrossRef

21.

Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep. 2003;10:333–8.PubMed

22.

Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer. 2004;110:362–7.PubMedCrossRef

23.

Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis-associated gene, MTA1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem. 1994;269:22958–63.PubMed

24.

Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, et al. Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 1997;74:459–63.PubMedCrossRef

25.

Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26:215–27.PubMedCrossRef

26.

Tzao C, Sun GH, Tung HJ, Hsu HS, Hsu WH, Wang YC, et al. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma. Ann Thorac Surg. 2006;82:396–401.PubMedCrossRef

27.

Soejima H, Nakagawachi T, Zhao W, Higashimoto K, Urano T, Matsukura S, et al. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer. Oncogene. 2004;23:4380–8.PubMedCrossRef

28.

Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143:1442–60.PubMedCrossRef

29.

Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.PubMedCrossRef

30.

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.PubMedCrossRef

31.

Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68:26–33.PubMedCrossRef

32.

Matsushima K, Isomoto H, Kohno S, Nakao K. MicroRNAs and esophageal squamous cell carcinoma. Digestion. 2010;82:138–44.PubMedCrossRef

33.

Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S, et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol. 2012;106:188–92.PubMedCrossRef

34.

Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 2009;15:1915–22.PubMedCrossRef

35.

Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Ogawa R, et al. MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma. Mol Med Rep. 2009;2:235–9.PubMed

36.

Ma WJ, Lv GD, Tuersun A, Liu Q, Liu H, Zheng ST, et al. Role of microRNA-21 and effect on PTEN in Kazakh’s esophageal squamous cell carcinoma. Mol Biol Rep. 2011;38:3253–60.PubMedCrossRef

37.

Kinoshita T, Hanazawa T, Nohata N, Okamoto Y, Seki N. The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet. 2012;57:556–63.PubMedCrossRef

38.

Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42.PubMedCrossRef

39.

Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 2011;9:30.PubMedCrossRef

40.

Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2012;104:48–54.PubMedCrossRef

41.

Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421:640–5.PubMedCrossRef

42.

Vallbohmer D, Brabender J, Metzger R, Holscher AH. Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg. 2010;14(Suppl 1):S75–80.PubMedCrossRef

43.

Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2012 (Epub ahead of print).

44.

Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008;3:336–41.PubMedCrossRef

45.

Adams L, Roth MJ, Abnet CC, Dawsey SP, Qiao YL, Wang GQ, et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev Res (Phila). 2008;1:357–61.CrossRef

46.

Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2001;7:3135–8.PubMed

47.

Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics. 2011;6:307–16.PubMedCrossRef

48.

Ling Y, Huang G, Fan L, Wei L, Zhu J, Liu Y, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol. 2011;64:246–51.PubMedCrossRef

49.

Ling ZQ, Zhao Q, Zhou SL, Mao WM. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2012;38:326–32.PubMedCrossRef

50.

Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:4917–21.PubMedCrossRef

51.

Gyobu K, Yamashita S, Matsuda Y, Igaki H, Niwa T, Oka D, et al. Identification and validation of DNA methylation markers to predict lymph node metastasis of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18:1185–94.PubMedCrossRef

52.

Huang S, Li XQ, Chen X, Che SM, Chen W, Zhang XZ. Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Dis Esophagus. 2012 (Epub ahead of print).

53.

Yang M, Liu R, Sheng J, Liao J, Wang Y, Pan E, et al. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep. 2013;29:169–76.PubMed

54.

Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer. 2012 (Epub ahead of print).

55.

Komatsu S, Ichikawa D, Takeshita H, Konishi H, Nagata H, Hirajima S, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther. 2012;12(Suppl 1):S53–9.PubMedCrossRef

56.

Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, et al. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res. 2009;29:4433–8.PubMed

57.

Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, et al. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncology. 2010;78:62–74.PubMedCrossRef

58.

Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, et al. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol. 2012;40:2140–6.PubMed

59.

Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.PubMedCrossRef

60.

Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009;69:1911–34.PubMedCrossRef

Title: Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma
Authors: Yasushi Toh
Akinori Egashira
Manabu Yamamoto
Publication date: 01-05-2013
Publisher: Springer Japan
Published in: General Thoracic and Cardiovascular Surgery / Issue 5/2013
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI: https://doi.org/10.1007/s11748-013-0235-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Urgent aortic valve replacement for infective endocarditis during the 23rd week of pregnancy

Perspectives: professionalism and cardio-thoracic surgery

Patient-prosthesis mismatch in patients with aortic valve replacement

Pulmonary lobar root clamping and stapling technique: return of the “en masse lobectomy”

Impact of novel off-pump coronary artery bypass simulator on the surgical training

Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis